HeraMED (ASX:HMD) Receipts from Customers: A$0.07 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is HeraMED Receipts from Customers?

HeraMED ASX:HMD +2.70% Receipts from Customers is A$0.07 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

HeraMED's Receipts from Customers for the six months ended in Dec. 2025 was A$0.00 Mil.

HeraMED's Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.07 Mil.

HeraMED Receipts from Customers Historical Data

* Premium members only.

The historical data trend for HeraMED's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED Receipts from Customers Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receipts from Customers
Get a 7-Day Free Trial 0.18 0.40 0.76 0.61 0.00

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.13 0.48 0.07 0.00

HeraMED Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Receipts from Customers of A$0.07 Mil mean?
HeraMED (ASX:HMD) has a Receipts from Customers of A$0.07 Mil as of Dec. 2025. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for HeraMED and its competitors.
Is HeraMED's Receipts from Customers too high?
HeraMED's current Receipts from Customers is A$0.07 Mil.
How does HeraMED's Receipts from Customers compare to ABT and SYK?
HeraMED's Receipts from Customers of A$0.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Medical Devices & Instruments company?
A good Receipts from Customers depends on the Medical Devices & Instruments industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for HeraMED and its competitors. HeraMED's current Receipts from Customers is A$0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 90% above its estimated fair value. The current Receipts from Customers is A$0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Receipts from Customers is A$0.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeraMED Business Description

Other Exchanges 1I4:Germany
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.